| Gene symbol | KRAS | Synonyms | C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras, K-Ras 2, KI-RAS, KRAS1, KRAS2, NS, NS3, OES, RALD, RASK2, c-Ki-ras, c-Ki-ras2 | Type of gene | protein-coding |
| Chromosome | 12 | Map location | 12p12.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | KRAS proto-oncogene, GTPase | ||||
| GTO ID | GTC2113 |
| Trial ID | NCT03948763 |
| Disease | Colorectal Carcinoma | Lung Non-Small Cell Carcinoma | Pancreatic Cancer |
| Altered gene | KRAS |
| Therapeutic/Target gene | Target gene |
| Therapy | mRNA vaccine |
| Treatment | V941|mRNA-5671 |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and in Combination With Pembrolizumab in Participants With KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma |
| Year | 2019 |
| Country | Australia|China|Korea,Republic of|New Zealand|Singapore|China|United States |
| Company sponsor | Merck Sharp & Dohme LLC |
| Other ID(s) | V941-001|V941-001 |
| Vector information | |||
|
|||
| Cohort1: V941 | |||||||||
|
|||||||||
| Cohort2: V941_Pembrolizumab | |||||||||
|
|||||||||